Influenza virus hemagglutinin antigenic site (HA antigenic site)

Influenza virus hemagglutinin antigenic sites are defined regions within the HA glycoprotein (particularly the globular head and stem domains) that are targeted by neutralizing antibodies during an immune response[1][2][7]. There are several classic sites (e.g., Sa, Sb, Ca1, Ca2, and Cb in H1 subtype; A, B, C, D, and E in H3 subtype) identified by their reactivity to monoclonal antibodies and their role in immune recognition[2][7]. These sites shape the antigenicity of influenza viruses, serving as the primary determinants of host immune response, dictating the subtype and strain-specific protection, and are the focal points for vaccine design and universal antibody strategies. Their constant mutation (antigenic drift) leads to escape from prior immunity and necessitates continual vaccine updates[2][7]. HA antigenic sites mediate host cell attachment through sialic acid binding and subsequent membrane fusion upon entry, with their structure and antigenic variation central to influenza’s infectivity, immune escape, and pandemic potential[1][3][4][7].

Other names

HA antigenic regionHemagglutinin epitopeInfluenza virus HA site

Neutralizing antibodies bind antigenic sites, preventing viral entry/fusion; Vaccines induce antibodies that block HA binding to host cell receptors